Skin cancer vaccine BLA submitted by...?
As of Tue, 20 Oct 2026 13:31:12 UTC, Polymarket traders price June 30, 2027? (65.5%), March 31, 2027 (48.5%). The market has $56K in volume and closes on Thu, 01 Jul 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| June 30, 2027? | 65.5% | 65.5¢ | 34.5¢ |
| March 31, 2027 | 48.5% | 48.5¢ | 51.5¢ |
Market details
- Venue: Polymarket
- Volume: $56K
- Liquidity: $10K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for June 30, 2027?:
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA). An original BLA or a resubmission of such a BLA following FDA action will qualify. The application may cover any indication. A qualifying announcement must come from the relevant company submitting the BLA, the FDA, or authorized representatives thereof. The submission must already have occurred at the time of the statement. A statement of intent, plan, guidance, or expected timing will not qualify. If the FDA grants approval of intismeran autogene on or before June 30, 2027, 11:59 PM ET, this market will resolve to "Yes", whether or not a submission was separately disclosed. The pri…
Sources
Related markets
- FDA approves Retatrutide this year?
- AI lab announces another Millennium Prize solution by...?
- U.S. enacts AI safety bill before 2027?
- Which Millennium Prize Problem will AI solve next?
- How many more Millennium Prize Problems will AI solve in 2026?
- Which math problems will AI solve in 2026?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.